Holmium-166 Radioembolization: Current Status and Future Prospective

M Stella; Arthur Braat; Rob van Rooij; Hugo de Jong; Marnix Lam

doi:10.1007/s00270-022-03187-y

Holmium-166 Radioembolization: Current Status and Future Prospective

M Stella, Arthur Braat, Rob van Rooij, Hugo de Jong, Marnix Lam

Research output: Contribution to journal › Review article › peer-review

24 Downloads (Pure)

Abstract

Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 (166Ho) caught the experts’ attention due to its imaging possibilities. Being not only a beta, but also a gamma emitter and a lanthanide, 166Ho can be imaged using single-photon emission computed tomography and magnetic resonance imaging, respectively. Another advantage of 166Ho is the possibility to perform the scout and treatment procedure with the same particle. This prospect paves the way to an individualized treatment procedure, gaining more control over dosimetry-based patient selection and treatment planning. In this review, an overview on 166Ho liver radioembolization will be presented. The current clinical workflow, together with the most relevant clinical findings and the future prospective will be provided.

Original language	English
Pages (from-to)	1634-1645
Number of pages	12
Journal	Cardiovascular and Interventional Radiology
Volume	45
Issue number	11
Early online date	21 Jun 2022
DOIs	https://doi.org/10.1007/s00270-022-03187-y
Publication status	Published - Nov 2022

Keywords

CT
Dosimetry
Holmium-166
MRI
Radioembolization
SPECT
SPECT/CT

Access to Document

10.1007/s00270-022-03187-yLicence: CC BY

s00270-022-03187-yFinal published version, 7.51 MBLicence: CC BY

Cite this

@article{ebf5a21605d94fc0b5fdac4bcd5d6a4d,

title = "Holmium-166 Radioembolization: Current Status and Future Prospective",

abstract = "Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 (166Ho) caught the experts{\textquoteright} attention due to its imaging possibilities. Being not only a beta, but also a gamma emitter and a lanthanide, 166Ho can be imaged using single-photon emission computed tomography and magnetic resonance imaging, respectively. Another advantage of 166Ho is the possibility to perform the scout and treatment procedure with the same particle. This prospect paves the way to an individualized treatment procedure, gaining more control over dosimetry-based patient selection and treatment planning. In this review, an overview on 166Ho liver radioembolization will be presented. The current clinical workflow, together with the most relevant clinical findings and the future prospective will be provided.",

keywords = "CT, Dosimetry, Holmium-166, MRI, Radioembolization, SPECT, SPECT/CT",

author = "M Stella and Arthur Braat and {van Rooij}, Rob and {de Jong}, Hugo and Marnix Lam",

note = "Funding Information: Funding for this study was received from NWO (Dutch Research Council), Project Number NWA.ID.17.059. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = nov,

doi = "10.1007/s00270-022-03187-y",

language = "English",

volume = "45",

pages = "1634--1645",

journal = "Cardiovascular and Interventional Radiology",

issn = "0174-1551",

publisher = "Springer-Verlag",

number = "11",

}

TY - JOUR

T1 - Holmium-166 Radioembolization: Current Status and Future Prospective

AU - Stella, M

AU - Braat, Arthur

AU - van Rooij, Rob

AU - de Jong, Hugo

AU - Lam, Marnix

PY - 2022/11

Y1 - 2022/11

N2 - Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 (166Ho) caught the experts’ attention due to its imaging possibilities. Being not only a beta, but also a gamma emitter and a lanthanide, 166Ho can be imaged using single-photon emission computed tomography and magnetic resonance imaging, respectively. Another advantage of 166Ho is the possibility to perform the scout and treatment procedure with the same particle. This prospect paves the way to an individualized treatment procedure, gaining more control over dosimetry-based patient selection and treatment planning. In this review, an overview on 166Ho liver radioembolization will be presented. The current clinical workflow, together with the most relevant clinical findings and the future prospective will be provided.

AB - Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 (166Ho) caught the experts’ attention due to its imaging possibilities. Being not only a beta, but also a gamma emitter and a lanthanide, 166Ho can be imaged using single-photon emission computed tomography and magnetic resonance imaging, respectively. Another advantage of 166Ho is the possibility to perform the scout and treatment procedure with the same particle. This prospect paves the way to an individualized treatment procedure, gaining more control over dosimetry-based patient selection and treatment planning. In this review, an overview on 166Ho liver radioembolization will be presented. The current clinical workflow, together with the most relevant clinical findings and the future prospective will be provided.

KW - CT

KW - Dosimetry

KW - Holmium-166

KW - MRI

KW - Radioembolization

KW - SPECT

KW - SPECT/CT

UR - http://www.scopus.com/inward/record.url?scp=85132341941&partnerID=8YFLogxK

U2 - 10.1007/s00270-022-03187-y

DO - 10.1007/s00270-022-03187-y

M3 - Review article

C2 - 35729423

SN - 0174-1551

VL - 45

SP - 1634

EP - 1645

JO - Cardiovascular and Interventional Radiology

JF - Cardiovascular and Interventional Radiology

IS - 11

ER -

Holmium-166 Radioembolization: Current Status and Future Prospective

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this